Login to Your Account



Other News To Note


Friday, February 11, 2011
Cytos Biotechnology Ltd., of Zurich, Switzerland, presented data on the mechanism of action of CYT003-QbG10 (QbG10) for the treatment of allergic asthma and rhinitis at the 3rd International Conference on Drug Discovery and Therapy in Dubai. QbG10 is a Toll-like receptor 9 agonist with clinical proof-of-concept in allergic asthma and rhinitis. The company said QbG10 controls asthma by directly inhibiting Th2 responses and by fostering the generation of regulatory T cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription